The U.S. Food and Drug Administration (FDA) was aware of reports of people developing suicidality after use of these drugs (example: Ozempic®/Wegovy®). After examining the available data, they recently reported, “Our preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions. … However, because of the small number of suicidal thoughts or actions observed in both people using GLP-1 RAs and in the comparative control groups, we cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to look into this issue.” (emphasis added)
Therefore, at this time, there is no reason to limit the use of these drugs in people with a psychiatric illness.